Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Recent insider selling by a senior executive may weigh on sentiment, though no major near-term operational catalysts are currently pending.
Senior Vice President, General Counsel, and Secretary Denton John Russel sold 7,500 shares of common stock on September 22, 2026, at a weighted average price of $31.8168. This transaction, disclosed in a Form 4 filing, represents a reduction in his direct holdings and may be viewed as a neutral-to-negative signal by market participants.
StockTitan